Identifying tomorrow’s success stories, today
How global thematic investing focuses on the best of business and megatrends.
With economies expected to take some time to recover from the impact of the COVID-19 pandemic, investors have to work harder to find promising long-term investments. The key for equity investors is to identify companies that are well positioned to expand through these challenging times and into the future – to find opportunities that may be currently underappreciated or undervalued by the markets.
One way to do this is through an approach called “global thematic investing.” This approach focuses on finding ways to capitalize on the megatrends that are changing the way we live, how society operates or how business is done. Its goal is to identify profitable companies operating in areas with the potential to thrive in the post-pandemic world.
Rather than looking backward at historical results, like many traditional investing strategies, global thematic investing looks forward, aiming to identify future success stories. Of course, one of the biggest megatrends today is a focus on health. That megatrend is likely to continue to benefit three areas in particular: health care, health care technology and biotechnology.
Health care – moving from competition to partnership
The health care sector, which includes pharmaceutical, life science and health care equipment companies, is at the forefront of the battle against COVID-19. Facing a common enemy, competitors are now working together towards a wide range of treatments and vaccines, and this collaborative approach has the potential to reinvigorate the industry. Specifically, the pandemic may leave a lasting positive legacy by shifting corporate priorities from short-term profits towards patient-centric solutions and sustainable earnings. This shift could make the sector an even more attractive source of long-term investments.
Health care technology – using IT to improve patient care
Health care technology encompasses a broad range of companies that put information technology innovation to work. Some are developing strategies to better manage the ever-growing volume of health-related information, including genome sequencing data, to identify those at higher risk and save lives. Others are developing software algorithms to predict how individuals will react to a specific drug and to check for potentially harmful drug interactions. There’s also a rich new field of health-promoting technologies, such as smart beds that adjust to help people enjoy better sleep. Even before the pandemic, this sector was set to more than double over five years to US$390 billion by 2024. Increased global interest in maximizing health should contribute to that growth.
Biotechnology – harnessing biology to solve big problems
Biotechnology makes useful products out of living systems. In COVID-19 vaccine development, some biotech companies are working to teach our bodies to be “bioreactors” by introducing the messenger RNA (mRNA) that builds viral proteins to stimulate antibody production. Others are growing antibodies in the lab that could serve as a vaccine or as a treatment for COVID-19. Scientists are also busy adapting a range of drugs to fight the pandemic, such as antivirals to stop or slow the replication of the virus in the body or drugs to help tackle serious complications during later stages of infection, such as suppressing immune overreaction.
Like other industries, biotechnology is not without risk as an investment. That said, because demand for medicine is not driven by economic cycles, biotech has generally performed well through past periods of market volatility, including the 2008 financial crisis.
Is this approach right for you?
Beyond a focus on health, other megatrends informing global thematic investing portfolio managers may include sustainability, democratization, commercialization and more. By first looking at the broad forces shaping our world, these portfolio managers seek to identify investment themes that are likely to benefit from the shifts these megatrends represent. The more megatrends at play in any area, the more compelling the investment theme becomes. What’s more, their strategies typically focus on companies providing solutions to global challenges and thus aim to deliver better outcomes not just for investors, but for everyone.
In the end, global thematic investing has the potential to uncover small to mid-sized companies that haven’t made it onto indexes yet but that have excellent future potential and may come to dominate the indexes of tomorrow.
ESG offers an additional layer of protection for investors because it makes sure the companies selected for a portfolio are treating the planet, their communities and their employees with respect. Companies with a high ESG score tend to be responsible corporate citizens, and that can translate into good stock performance. In an area like global thematic investing, ESG analysis offers a different lens to identify potential future risks to a company, as well as providing reassurance to investors that the companies they own have priorities that match theirs.
If you would like to learn more about ESG investments please reach out to one of our advisors.
We continue to serve you and if you have questions about the markets or your investments, we are here to talk. For your safety and convenience, we are doing client meetings by phone, Skype, Zoom, or porch visits. While we may work from home, we have protocols in place to do in-person meetings at our office, with masks, sanitation, and limited people. If you would like a portfolio review or updated financial plan, you can always reach us to schedule an appointment by contacting Terry at firstname.lastname@example.org and (289) 479-5059 or Diana email@example.com and (289) 479-5512.
- David Wyatt, BA, B.Comm, CFP, Senior Investment Advisor, Manulife Securities Incorporated
- Elaine Kelly, MBA CFP, FCSI, Senior Investment Advisor, Manulife Securities Incorporated
- Katlin Wyatt, BA, Investment Advisor, Manulife Securities Incorporated
- Diana Kancko, Executive Assistant, Manulife Securities Incorporated
- Terry Wyatt, Executive Assistan, Manulife Securities Incorporated
© 2020 Manulife. The persons and situations depicted are fictional and their resemblance to anyone living or dead is purely coincidental. This media is for information purposes only and is not intended to provide specific financial, tax, legal, accounting or other advice and should not be relied upon in that regard. Many of the issues discussed will vary by province. Individuals should seek the advice of professionals to ensure that any action taken with respect to this information is appropriate to their specific situation. E & O E. Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the fund facts as well as the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. Any amount that is allocated to a segregated fund is invested at the risk of the contractholder and may increase or decrease in value. www.manulife.ca/accessibility
Manulife Securities Incorporated. does not make any representation that the information provided in the 3rd Party articles is accurate and will not accept any responsibility or liability for any inaccuracies in the information or content of any 3rd party articles. Any opinion or advice expressed in the 3rd party article, including the opinion of a Manulife Securities Advisor, should not be construed as, and may not reflect, the opinion or advice of Manulife Securities. The 3rd party articles are provided for information purposes only and are not meant to provide legal accounting or account advice.”
This publication contains opinions of the writer and may not reflect opinions of Manulife Securities Incorporated. The information contained herein was obtained from sources believed to be reliable, but no representation, or warranty, express or implied, is made by the writer or Manulife Securities Incorporated or any other person as to its accuracy, completeness or correctness. This publication is not an offer to sell or a solicitation of an offer to buy any of the securities. The securities discussed in this publication may not be eligible for sale in some jurisdictions. If you are not a Canadian resident, this report should not have been delivered to you. This publication is not meant to provide legal or account advice. As each situation is different you should consult your own professional Advisors for advice based on your specific circumstances.